INOVIO to Present at Upcoming Scientific Conferences

Rhea-AI Summary

INOVIO (NASDAQ:INO) announced its participation in two major scientific conferences. At the 36th International Papillomavirus Conference in Edinburgh (Nov 12-15), the company will present research on INO-3107's treatment of recurrent respiratory papillomatosis, including studies on interferon responses and T-cell activity. At the Vaccines Summit in Boston (Nov 13-15), Dr. Dave Liebowitz will deliver a keynote on DNA Medicines Vaccine Platform, focusing on Ebola and respiratory papillomatosis case studies. All conference abstracts will be available on INOVIO's website after presentations.

News Market Reaction

-2.65%

1 alert

-2.65% News Effect

On the day this news was published, INO declined 2.65%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

PLYMOUTH MEETING, Pa., Nov. 6, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will present at the following scientific conferences:

36th International Papillomavirus Conference (Edinburgh, UK; November 12-15)

Presentation and poster by Dr. Matthew Morrow, VP of Translational Sciences
Abstract Title: Treatment of recurrent respiratory papillomatosis with INO-3107 induces significant enrichment in hallmark interferon alpha, interferon gamma and inflammatory molecular signatures in papilloma tissue of responders

Poster by Dr. Jeffrey Skolnik, SVP of Clinical Development
Abstract Title: Clinical response to INO-3107 treatment for recurrent respiratory papillomatosis is associated with CD4 and CD8 T-Cell activity and cytotoxicity in patient airways

Vaccines Summit (Boston, MA; November 13-15)

Keynote presentation by Dr. Dave Liebowitz, SVP Early-Stage Clinical Development
Abstract Title: DNA Medicines Vaccine Platform for both Prophylactic and Therapeutic Applications: Case Studies in Ebola and Recurrent Respiratory Papillomatosis

Abstracts from these conferences will be made available on INOVIO's website following each presentation.

About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.

Contacts
Media: Jennie Willson (267) 429-8567 jennie.willson@inovio.com
Investors: Thomas Hong (267) 440-4298 thomas.hong@inovio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/inovio-to-present-at-upcoming-scientific-conferences-302297797.html

SOURCE INOVIO Pharmaceuticals, Inc.

FAQ

What conferences will INOVIO (INO) present at in November 2024?

INOVIO will present at the 36th International Papillomavirus Conference in Edinburgh (Nov 12-15) and the Vaccines Summit in Boston (Nov 13-15).

What will INOVIO (INO) present about INO-3107 at the Papillomavirus Conference?

INOVIO will present research on INO-3107's treatment of recurrent respiratory papillomatosis, including studies on interferon responses and T-cell activity in patient airways.

What is the topic of INOVIO's (INO) keynote presentation at the 2024 Vaccines Summit?

Dr. Dave Liebowitz will present on DNA Medicines Vaccine Platform for prophylactic and therapeutic applications, focusing on Ebola and recurrent respiratory papillomatosis case studies.